SG11201807548SA - Inducible binding proteins and methods of use - Google Patents
Inducible binding proteins and methods of useInfo
- Publication number
- SG11201807548SA SG11201807548SA SG11201807548SA SG11201807548SA SG11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA SG 11201807548S A SG11201807548S A SG 11201807548SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- san francisco
- pct
- applicant
- street
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108091008324 binding proteins Proteins 0.000 title abstract 2
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- RBSXHDIPCIWOMG-UHFFFAOYSA-N 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethylsulfonylimidazo[1,2-a]pyridin-3-yl)sulfonylurea Chemical compound CCS(=O)(=O)C=1N=C2C=CC=CN2C=1S(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 RBSXHDIPCIWOMG-UHFFFAOYSA-N 0.000 abstract 1
- 241000721662 Juniperus Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 0101111101110111011011010111 10111110H III International Bureau .. .... ..Yejd (10) International Publication Number ..... .....!;,,, (43) International Publication Date WO 2017/156178 Al 14 September 2017 (14.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07K 16/28 (2006.01) C07K 16/30 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/18 (2006.01) A61K 39/395 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2017/021435 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 8 March 2017 (08.03.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/305,092 8 March 2016 (08.03.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: MAVERICK THERAPEUTICS, INC. GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [US/US]; 3260 B Bayshore Blvd., 1st Floor, Brisbane, CA TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 94005 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, — (72) Inventors: BAEUERLE, Patrick; Waldpromenade 18c, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, L 82131 Gauting (DE). DUBRIDGE, Robert, B.; 825 Holly V, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Road, Belmont, CA 94002 (US). WESCHE, Holger; 1080 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Jamestown Avenue, San Francisco, CA 94124 (US). EVN- — IN, Luke; 768 El Camino Del Mar, San Francisco, CA Declarations under Rule 4.17: 94121 (US). GUENOT, Jeanmarie; 45 Juniper Street, #3, — as to applicant's entitlement to apply for and be granted a San Francisco, CA 94103 (US). PANCHAL, Anand; 2615 patent (Rule 4.1700) Turk Street, Apt A., San Francisco, CA 94118 (US). VINOGRADOVA, Maia; 2079 Ascot Drive, Unit 240, — as to the applicant's entitlement to claim the priority of the = Moraga, CA 94556 (US). earlier application (Rule 4. 1 7(iii)) Agents: MANN, Jeffry S. et al.; Morgan, Lewis & Bocki- Published: (74) us LLP, One Market Spear Street Tower, San Francisco, _ with international search report (Art. 21(3)) CA 94105 (US). = — = = Title: INDUCIBLE BINDING PROTEINS AND METHODS OF USE (54) FIG. 3 = = anti-CD3 anti-EGFR = = sePv 7 Ab C — EK Cleavable Linkers = — anti-CD3 . 4 :, •- '''. e, scFv 1 'Zt Proteolytk ' ss ‘ ,..,_ ''''' Cleavage — ''', E by EK : a nti-EGFR — \\, G8 sdAb vi .4 ail .1 N GC IN Il Cancer Cell ,tD 11 in ,—, IN 1-1 (57) : Provided herein are conditionally activated polypeptide constructs comprising a protease-activated domain binding to 0 CD3, at least one half-life extension domain, and two or more domains binding to one or more target antigens. Also provided are \" h p armaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such poly- peptide constructs. Also disclosed are methods of using the disclosed polypeptide constructs in the prevention, and/or treatment dis - .• eases, conditions and disorders.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305092P | 2016-03-08 | 2016-03-08 | |
| PCT/US2017/021435 WO2017156178A1 (en) | 2016-03-08 | 2017-03-08 | Inducible binding proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807548SA true SG11201807548SA (en) | 2018-09-27 |
Family
ID=59789722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807548SA SG11201807548SA (en) | 2016-03-08 | 2017-03-08 | Inducible binding proteins and methods of use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180134789A1 (en) |
| EP (1) | EP3426689A4 (en) |
| JP (3) | JP7195927B2 (en) |
| KR (2) | KR102501921B1 (en) |
| CN (1) | CN109071667A (en) |
| AU (1) | AU2017229687A1 (en) |
| BR (1) | BR112018068189A2 (en) |
| CA (1) | CA3016165A1 (en) |
| IL (1) | IL261432B2 (en) |
| MA (1) | MA43816A (en) |
| MX (1) | MX2018010824A (en) |
| SG (1) | SG11201807548SA (en) |
| TW (2) | TW201808990A (en) |
| WO (1) | WO2017156178A1 (en) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6688551B2 (en) | 2015-05-21 | 2020-04-28 | ハープーン セラピューティクス，インク． | Trispecific binding proteins and methods of use |
| CA3003482A1 (en) | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
| CA3024683A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
| PL3445787T3 (en) | 2016-10-07 | 2021-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| BR112019010602A2 (en) | 2016-11-23 | 2019-12-17 | Harpoon Therapeutics Inc | trispecific psma proteins and methods of use |
| KR20210087108A (en) | 2016-11-23 | 2021-07-09 | 하푼 테라퓨틱스, 인크. | Prostate specific membrane antigen binding protein |
| WO2018160671A1 (en) * | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Targeted checkpoint inhibitors and methods of use |
| WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| WO2018204717A1 (en) * | 2017-05-03 | 2018-11-08 | Harpoon Therapeutics, Inc. | Compositions and methods for adoptive cell therapies |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| CN115028727A (en) | 2017-05-12 | 2022-09-09 | 哈普恩治疗公司 | MSLN-targeting trispecific proteins and methods of use |
| CN111315773A (en) | 2017-09-08 | 2020-06-19 | 马弗里克治疗公司 | Conditionally active binding moieties comprising an Fc region |
| CN111356700A (en) | 2017-09-08 | 2020-06-30 | 马弗里克治疗公司 | Constrained conditionally activated binding proteins |
| WO2019075359A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
| EP3694871A4 (en) | 2017-10-13 | 2021-11-10 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
| CA3080429A1 (en) * | 2017-11-01 | 2019-05-09 | Nantbio, Inc. | Il8 blocking emt pathway and overcoming cancer stem cells |
| CN110218253B (en) * | 2018-03-02 | 2020-12-04 | 广西医科大学 | CD 3-resistant nano antibody CD3/Nb14 and preparation method and application thereof |
| CN110218256B (en) * | 2018-03-02 | 2020-12-08 | 广西医科大学 | CD 3-resistant nano antibody CD3/Nb29 and preparation method and application thereof |
| CA3100007A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| CN112654635A (en) | 2018-05-14 | 2021-04-13 | 狼人治疗公司 | Activatable cytokine polypeptides and methods of use thereof |
| KR20210020903A (en) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | Binding moieties for conditional activation of immunoglobulin molecules |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| KR20210038548A (en) | 2018-06-22 | 2021-04-07 | 큐진 인크. | Cytokine-based bioactive drugs and methods of use thereof |
| JP2021533744A (en) | 2018-08-09 | 2021-12-09 | マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. | Methods for co-expressing and purifying conditionally activated binding proteins |
| MX2021003554A (en) | 2018-09-25 | 2021-05-27 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use. |
| KR20210134091A (en) * | 2019-01-29 | 2021-11-08 | 그릿스톤 바이오, 인코포레이티드 | multispecific binding protein |
| WO2020181145A1 (en) | 2019-03-05 | 2020-09-10 | Maverick Therapeutics, Inc. | Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens |
| US11685780B2 (en) | 2019-03-05 | 2023-06-27 | Takeda Pharmaceutical Company Limited | Single domain antigen binding domains that bind human Trop2 |
| MX2021013766A (en) | 2019-05-14 | 2022-02-21 | Werewolf Therapeutics Inc | Separation moieties and methods and use thereof. |
| WO2021097060A1 (en) * | 2019-11-13 | 2021-05-20 | Harpoon Therapeutics, Inc. | Pro immune modulating molecule comprising a clustering moiety |
| CN114829408B (en) * | 2019-12-20 | 2024-01-26 | 山东博安生物技术股份有限公司 | Optimized anti-CD3 arms in T cell bispecific antibody production for immunotherapy |
| EP4090686A4 (en) * | 2020-01-17 | 2024-03-27 | Immune Targeting Inc | Pro-antibody that reduces off-target toxicity |
| KR20220144841A (en) | 2020-02-21 | 2022-10-27 | 하푼 테라퓨틱스, 인크. | FLT3 Binding Proteins and Methods of Use |
| MX2022011780A (en) | 2020-04-09 | 2022-11-10 | Cytomx Therapeutics Inc | Compositions containing activatable antibodies. |
| WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
| PE20230856A1 (en) | 2020-08-17 | 2023-05-29 | Takeda Pharmaceuticals Co | CONDITIONALLY ACTIVATED RESTRICTED BINDING PROTEINS |
| CA3184037A1 (en) * | 2020-08-18 | 2022-02-24 | Onchilles Pharma, Inc. | Modified serine protease proproteins |
| US11617767B2 (en) | 2020-11-20 | 2023-04-04 | Simcere Innovation, Inc. | Armed dual CAR-T compositions and methods for cancer immunotherapy |
| TW202237654A (en) | 2020-12-09 | 2022-10-01 | 美商詹努克斯治療有限公司 | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2022214978A1 (en) | 2021-04-06 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Therapeutic methods using constrained conditionally activated binding proteins |
| WO2022235940A1 (en) | 2021-05-06 | 2022-11-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
| WO2023034288A1 (en) | 2021-08-31 | 2023-03-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treatment of autoimmune disorders and cancer |
| WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
| WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
| WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
| WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
| WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2005141512A (en) * | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | PHARMACEUTICAL COMPOSITIONS, INCLUDING BISPECIFIC ANTI-CD3, ANTI-CD19 ANTIBODY STRUCTURES FOR TREATMENT OF B-CELL DISORDERS |
| DK1673398T3 (en) * | 2003-10-16 | 2011-04-18 | Micromet Ag | Multispecific, deimmunized CD3 binders |
| US20070269422A1 (en) * | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| RU2013110876A (en) * | 2010-08-24 | 2014-09-27 | Рош Гликарт Аг | ACTIVATED SPECIFIC ANTIBODIES |
| US20120225081A1 (en) * | 2010-09-03 | 2012-09-06 | Boehringer Ingelheim International Gmbh | Vegf-binding molecules |
| UA115122C2 (en) * | 2011-05-21 | 2017-09-25 | Макродженікс, Інк. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| US9382305B2 (en) * | 2011-07-01 | 2016-07-05 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| IN2014DN05756A (en) * | 2012-02-27 | 2015-04-10 | Boehringer Ingelheim Int | |
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2013128027A1 (en) * | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
| US20140004121A1 (en) * | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
| CA2912389C (en) * | 2013-06-10 | 2020-01-28 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| AU2015237184B2 (en) * | 2014-03-28 | 2020-11-26 | Xencor, Inc. | Bispecific antibodies that bind to CD38 and CD3 |
| CA3003482A1 (en) * | 2015-11-19 | 2017-05-26 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| JP2021533744A (en) * | 2018-08-09 | 2021-12-09 | マベリック セラピューティクス, インコーポレイテッドMaverick Therapeutics, Inc. | Methods for co-expressing and purifying conditionally activated binding proteins |
-
2017
- 2017-03-08 KR KR1020187029014A patent/KR102501921B1/en active IP Right Grant
- 2017-03-08 BR BR112018068189A patent/BR112018068189A2/en unknown
- 2017-03-08 SG SG11201807548SA patent/SG11201807548SA/en unknown
- 2017-03-08 MX MX2018010824A patent/MX2018010824A/en unknown
- 2017-03-08 WO PCT/US2017/021435 patent/WO2017156178A1/en active Application Filing
- 2017-03-08 JP JP2018547940A patent/JP7195927B2/en active Active
- 2017-03-08 AU AU2017229687A patent/AU2017229687A1/en active Pending
- 2017-03-08 MA MA043816A patent/MA43816A/en unknown
- 2017-03-08 TW TW106107861A patent/TW201808990A/en unknown
- 2017-03-08 CN CN201780028480.4A patent/CN109071667A/en active Pending
- 2017-03-08 KR KR1020237005284A patent/KR20230041739A/en not_active Application Discontinuation
- 2017-03-08 EP EP17764037.2A patent/EP3426689A4/en active Pending
- 2017-03-08 TW TW111119065A patent/TW202302631A/en unknown
- 2017-03-08 CA CA3016165A patent/CA3016165A1/en active Pending
- 2017-03-08 IL IL261432A patent/IL261432B2/en unknown
- 2017-10-06 US US15/727,423 patent/US20180134789A1/en not_active Abandoned
-
2022
- 2022-05-18 JP JP2022081366A patent/JP7293456B2/en active Active
-
2023
- 2023-06-07 JP JP2023093681A patent/JP2023123519A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022140856A (en) | 2022-09-28 |
| WO2017156178A1 (en) | 2017-09-14 |
| MX2018010824A (en) | 2019-05-15 |
| EP3426689A1 (en) | 2019-01-16 |
| CA3016165A1 (en) | 2017-09-14 |
| BR112018068189A2 (en) | 2019-02-05 |
| KR20180120245A (en) | 2018-11-05 |
| JP7293456B2 (en) | 2023-06-19 |
| IL261432B2 (en) | 2024-03-01 |
| IL261432B1 (en) | 2023-11-01 |
| JP2023123519A (en) | 2023-09-05 |
| KR20230041739A (en) | 2023-03-24 |
| JP2019513014A (en) | 2019-05-23 |
| RU2018134949A (en) | 2020-04-08 |
| TW201808990A (en) | 2018-03-16 |
| MA43816A (en) | 2018-11-28 |
| US20180134789A1 (en) | 2018-05-17 |
| RU2018134949A3 (en) | 2020-08-14 |
| EP3426689A4 (en) | 2020-01-15 |
| KR102501921B1 (en) | 2023-02-21 |
| CN109071667A (en) | 2018-12-21 |
| TW202302631A (en) | 2023-01-16 |
| JP7195927B2 (en) | 2022-12-26 |
| AU2017229687A1 (en) | 2018-09-20 |
| IL261432A (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807548SA (en) | Inducible binding proteins and methods of use | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201809041TA (en) | Compositions and methods for selective protein expression | |
| SG11201811600PA (en) | Pseudotyped oncolytic viral delivery of therapeutic polypeptides | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201804713VA (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| SG11201806261XA (en) | Bcma antibodies and use of same to treat cancer and immunological disorders | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201808913WA (en) | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201810327XA (en) | Single domain serum albumin binding protein | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201805375PA (en) | Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity | |
| SG11201806392XA (en) | Personalized delivery vector-based immunotherapy and uses thereof |